Lahdenperä Arttu, Koivusalo Anna-Maria, Vakkuri Anne, Höckerstedt Krister, Isoniemi Helena
Department of Anaesthesiology and Intensive Care, Helsinki University Hospital, Helsinki, Finland.
Transpl Int. 2005 Jan;17(11):717-23. doi: 10.1007/s00147-004-0796-2. Epub 2004 Dec 3.
A blood purification system, molecular adsorbents re-circulating system (MARS), is based on the removal of both protein-bound and water-soluble substances and toxins in the liver. We treated a total of 88 patients within 2 years. Of these patients, 45 had acute liver failure (ALF), 31 had acute decompensation of chronic liver disease, eight had graft failure and four had miscellaneous conditions. Of the patients with ALF, 80% survived; in 23 patients their own liver recovered and 13 patients underwent successful transplantation. Only 23% of patients with acute-on-chronic liver failure survived. Most of them were not considered for transplantation due to their having liver failure from alcoholism and from not abstaining from drinking. MARS is a promising therapy for ALF, allowing the patient's own liver to recover or allowing enough time to find a liver graft. Best results were achieved in patients who had been intoxicated with a lethal dose of toxin. On the other hand, we did not observe much benefit in patients with severe acute-on-chronic liver failure (AcoChr) who did not undergo liver transplantation.
一种血液净化系统,即分子吸附剂循环系统(MARS),基于对肝脏中蛋白结合物、水溶性物质及毒素的清除。我们在2年内共治疗了88例患者。其中,45例为急性肝衰竭(ALF),31例为慢性肝病急性失代偿,8例为移植失败,4例为其他情况。在急性肝衰竭患者中,80%存活;23例患者自身肝脏恢复,13例患者成功接受移植。慢性肝衰竭急性发作患者中只有23%存活。他们中的大多数因酒精性肝衰竭且未戒酒而未被考虑进行移植。MARS是治疗急性肝衰竭的一种有前景的疗法,能使患者自身肝脏恢复或争取足够时间找到肝源进行移植。在因致死剂量毒素中毒的患者中取得了最佳效果。另一方面,我们发现对于未接受肝移植的严重慢性肝衰竭急性发作(AcoChr)患者,未观察到太多益处。